help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bierwolf, C.
Right arrow Articles by Fehm, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bierwolf, C.
Right arrow Articles by Fehm, H. L.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 4 1151-1157
Copyright © 1998 by The Endocrine Society


Original Articles

Influence of Exogenous Atrial Natriuretic Peptide on the Pituitary-Adrenal Response to Corticotropin-Releasing Hormone and Vasopressin in Healthy Men

Claudia Bierwolf, Axel Burgemeister, Karen Lüthke, Jan Born and Horst L. Fehm

Clinical Neuroendocrinology and Department of Internal Medicine, University of Lübeck, 23538 Lübeck, Germany

Address all correspondence and requests for reprints to: J. Born, Ph.D., Medizinische Universität zu Lübeck, Klinische Forschergruppe, Haus 23a, Ratzeburger Allee 160, 23538 Lübeck, Germany.

Abstract

Atrial natriuretic peptide (ANP) has been considered a potential candidate participating in the inhibitory control of pituitary-adrenal secretory activity. Here, we investigated the influence of ANP, infused at two different doses and over infusion intervals of two different durations, on the release of ACTH and cortisol after stimulation with CRH and with combined administration of CRH and vasopressin (VP). In young healthy men, three experiments were conducted. In Exp I, ACTH/cortisol secretory responses to CRH (50 µg) were examined during and after a 45-min period of ANP infusion at a rate of 4.4 µg/min (starting 15 min before CRH injection). In Exp II, ACTH/cortisol secretory responses to CRH (50 µg) were examined during and after a 90-min infusion period of ANP administered at rates of 4.4 and 8.8 µg/min. In Exp III, ANP was infused at a rate of 4.4 µg/min over 90 min, but instead of CRH, a combined administration of CRH (50 µg) and VP (0.5 IU infused within 5 min) was employed to stimulate ACTH/cortisol release. ANP diminished pituitary-adrenal secretory responses within the first hour after stimulation with exogenous secretagogues. Thereafter, the effect of ANP turned in the opposite direction, with distinctly enhanced concentrations of ACTH and cortisol during the third hour after stimulation. The inhibitory effect of ANP during the first hour of the pituitary-adrenal response was more pronounced on concentrations of cortisol than ACTH and was also more pronounced after combined administration of CRH/VP than after stimulation with CRH alone. Increasing the dose of ANP enhanced the late stimulatory effect on ACTH/cortisol release, thereby terminating the early period of inhibited ACTH/cortisol release more abruptly. The late stimulatory effect was enhanced with prolonged infusion of ANP. In addition, it was associated with reduced hematocrit, increased urine volumes collected, increased heart rate, and enhanced plasma VP concentrations. Together, these changes suggest that the late stimulatory effect of ANP on ACTH/cortisol release reflects an effect secondary to its hypovolemic actions. This stimulatory effect originating from peripheral systemic actions of ANP after exogenous administration appears to override a more direct inhibitory action of the peptide on pituitary-adrenal secretory activity. Therefore, we would expect that with localized release into portal hypophyseal blood the inhibitory component of the action of ANP on pituitary-adrenal secretory activity prevails.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. Perras, B. Schultes, B. Behn, C. Dodt, J. Born, and H. L. Fehm
Intranasal Atrial Natriuretic Peptide Acts as Central Nervous Inhibitor of the Hypothalamo-Pituitary-Adrenal Stress System in Humans
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4642 - 4648.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. L. Vesely, G. I. San Miguel, I. Hassan, and D. D. Schocken
Atrial Natriuretic Hormone, Vessel Dilator, Long-Acting Natriuretic Hormone, and Kaliuretic Hormone Decrease the Circulating Concentrations of CRH, Corticotropin, and Cortisol
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4244 - 4249.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
K. Wiedemann, H. Jahn, A. Yassouridis, and M. Kellner
Anxiolyticlike Effects of Atrial Natriuretic Peptide on Cholecystokinin Tetrapeptide-Induced Panic Attacks: Preliminary Findings
Arch Gen Psychiatry, April 1, 2001; 58(4): 371 - 377.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society